News Scholar Rock Holding Corporation

Stocks

SRRK

US80706P1030

Biotechnology & Medical Research

Market Closed - Nasdaq 00:00:00 22/08/2026 +04			5-day change	1st Jan Change
56.50 ^USD	+2.26%		+7.58%	+28.26%

11:04pm	Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says	MT
08:46pm	Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating	MT

All News

Mentions Relevance

11:04pm	Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says	MT
08:46pm	Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating	MT
06:45pm	Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission	RE
06:20pm	Scholar Rock Announces Removal Of Catalent Indiana As Fill-Finish Facility And Progresses Apitegromab Regulatory Filings With FDA, EMA, And PMDA	CI
05:50pm	Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan	CI
05:36pm	Scholar Rock Removes Catalent Indiana From Apitegromab BLA as Fill-Finish Facility	MT
05:07pm	Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan	BU
08-15	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
08-10	Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date	MT
08-08	Scholar Rock drops Novo Nordisk facility from marketing application for muscle weakness drug	RE
08-08	Scholar Rock Holdings Pulls Novo Nordisk Facility From Drug Application After FDA Flag	DJ
08-08	Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date	MT
08-08	Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date	BU
08-06	Scholar Rock Holding Corporation, Q2 2026 Earnings Call, Aug 06, 2026
08-06	Scholar Rock Holding Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Scholar Rock Q2 Net Loss Narrows	MT
08-06	Scholar Rock Reports Apitegromab Biologics License Application Progress, Initiates Phase 2 Forge Study, and Provides Updates on Srk-439 and Opal Trials	CI
08-06	Earnings Flash (SRRK) Scholar Rock Posts Q2 Loss of $0.84 a Share, vs. FactSet Est of $0.84 Loss	MT
08-06	Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights	BU
07-29	Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference	BU
07-20	Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026	RE
07-20	Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)	BU
07-18	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
07-16	Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026	BU
06-22	Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD	BU